Lanadelumab

證據等級: L5

預測適應症: 10 個

Lanadelumab: From Hereditary Angioedema Prophylaxis to C1 Inhibitor Deficiency

One-Sentence Summary

Lanadelumab is a fully human monoclonal antibody that inhibits plasma kallikrein, already approved and marketed in multiple countries (e.g., Japan, South Korea, China, Argentina — as documented in the trial records below) for long-term prophylaxis of hereditary angioedema (HAE) attacks. The TxGNN model's top prediction, C1 inhibitor deficiency, is supported by 24 clinical trials and 20 publications. Note, however, that C1 inhibitor deficiency is the underlying genetic defect that causes HAE — the disease lanadelumab already treats — so this result largely confirms the model's accuracy rather than identifying a genuinely novel repurposing opportunity.

Quick Overview

Item	Content
Original Indication	Hereditary Angioedema (HAE) prophylaxis (per trial records; formal MOA/original-indication fields in this evidence pack are marked as data gaps)
Predicted New Indication	C1 inhibitor deficiency
TxGNN Prediction Score	99.9955%
Evidence Level	L2 (1 completed Phase 3 RCT — HELP Study; remaining Phase 3 trials are open-label/expanded-access/observational)
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

The original_moa field in this evidence pack is marked as a data gap. However, based on literature evidence collected in this pack (PMID 30267321), lanadelumab is documented as a fully human monoclonal antibody that inhibits plasma kallikrein, reducing bradykinin generation within the kallikrein-kinin pathway.

C1 inhibitor (encoded by SERPING1) is the physiological regulator of plasma kallikrein. When C1-INH is deficient or dysfunctional (HAE Type I/II), kallikrein activity becomes unregulated, driving excess bradykinin production and the vascular permeability that causes HAE attacks. Lanadelumab does not replace C1-INH itself, but inhibits the same downstream enzyme (kallikrein) that C1-INH normally regulates — which is why it is already an approved, first-line long-term prophylactic therapy for HAE due to C1-INH deficiency in numerous markets referenced in the trial data below (Japan, South Korea, China, Argentina, UK, Poland, Saudi Arabia).

Because "C1 inhibitor deficiency" is essentially synonymous with the disease population lanadelumab already treats, this TxGNN prediction should be interpreted as a validation signal for the model rather than a new therapeutic hypothesis requiring independent proof-of-concept.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02586805	Phase 3	Completed	125	HELP Study — pivotal randomized, double-blind, placebo-controlled trial demonstrating efficacy of lanadelumab (DX-2930) in preventing HAE attacks (Type I/II)
NCT02741596	Phase 3	Completed	212	HELP Study Extension — open-label long-term safety and efficacy follow-up
NCT05460325	Phase 3	Completed	20	Safety, PK, and efficacy of lanadelumab in Chinese HAE patients over 26 weeks
NCT04180163	Phase 3	Completed	12	Efficacy and safety of lanadelumab in Japanese HAE Type I/II patients
NCT04070326	Phase 3	Completed	21	SPRING Study — PK/PD and efficacy of lanadelumab in pediatric patients (2–<12 years)
NCT04444895	Phase 3	Completed	73	Long-term safety/efficacy in non-histaminergic angioedema with normal C1-INH
NCT04687137	Phase 3	Completed	12	Japan expanded access program for HAE Type I/II
NCT01923207	Phase 1	Completed	32	First-in-human single ascending dose safety/PK study (healthy subjects)
NCT02093923	Phase 1	Completed	38	Multiple ascending dose safety/tolerability/PK study in HAE subjects
NCT03845400	N/A	Completed	168	EMPOWER Study — real-world observational attack-rate comparison (US/Canada)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30480729	2018	RCT	JAMA	Lanadelumab significantly reduced HAE attack frequency vs. placebo (HELP Study primary publication)
32187470	2020	Review	N Engl J Med	Overview of HAE pathophysiology, C1-INH deficiency, and treatment landscape
39508959	2024	Systematic Review	Clin Rev Allergy Immunol	Breakthrough attacks in HAE patients on long-term prophylaxis, including lanadelumab
33602658	2021	Review	J Investig Allergol Clin Immunol	Current and emerging therapies for C1-INH-HAE, including kallikrein inhibition
30267321	2018	Review	Drugs	"Lanadelumab: First Global Approval" — MOA and regulatory approval summary
34287942	2022	Open-Label Extension	Allergy	HELP OLE Study — long-term effectiveness/safety data (NCT02741596)
39701274	2025	Real-World/Observational	J Allergy Clin Immunol Pract	Multicountry INTEGRATED study on real-world effectiveness of lanadelumab
40434599	2025	Network Meta-Analysis	Drugs R D	Comparative efficacy/safety of HAE long-term prophylaxis agents (lanadelumab, garadacimab, berotralstat, C1-INH)
37898409	2024	Review	J Allergy Clin Immunol	Disease burden of C1-INH deficiency in the Asia-Pacific region
30539362	2019	Review	BioDrugs	Preclinical and Phase I data review of lanadelumab for C1-INH-HAE prophylaxis

Germany Market Information

Lanadelumab currently has no marketing authorization on record in this evidence pack (market_status: 未上市 / Not Marketed; total_licenses: 0). No license table can be generated.

Safety Considerations

Detailed safety data (key warnings, contraindications, drug-drug interactions) are flagged as data gaps in this evidence pack (DG001, severity: Blocking) and could not be retrieved from a formal source (e.g., BfArM/EMA label). This gap specifically blocks progression to the S1 safety pre-assessment stage.

Please refer to the official package insert / EMA SmPC for safety information once available.

Conclusion and Next Steps

Decision: Hold

Rationale:

Efficacy evidence for lanadelumab in HAE/C1-INH-deficiency-related indications is strong (1 completed Phase 3 RCT plus extensive supporting Phase 3 and real-world data), but this largely reflects the drug's already-established indication rather than a novel repurposing candidate.
A Blocking-severity data gap (DG001: missing formal warnings/contraindications) prevents this candidate from proceeding to the S1 safety pre-assessment, per the evidence pack's own gap classification.

To proceed, the following is needed:

Retrieve official label/SmPC data (warnings, contraindications, DDI) from BfArM/EMA to close DG001 before any safety pre-assessment.
Confirm and document the original MOA (DG002) from a primary regulatory source rather than secondary literature.
Clarify scope: since "C1 inhibitor deficiency" overlaps with lanadelumab's known approved use, determine whether this candidate should instead be tracked as a market-entry assessment for Germany rather than a repurposing candidate.
If genuine repurposing value is sought, evaluate lower-ranked candidates (e.g., non-histaminergic angioedema with normal C1-INH, supported by NCT04444895/PMID 37780787) which represent more distinct indications from the approved label.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.